Critical Contrast: Enlivex Therapeutics (NASDAQ:ENLV) & Surrozen (NASDAQ:SRZN)

Surrozen (NASDAQ:SRZN) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility & Risk

Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Surrozen and Enlivex Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2	0	3	1	2.50
Enlivex Therapeutics	1	1	1	0	2.00

Surrozen presently has a consensus price target of $42.00, indicating a potential upside of 68.54%. Enlivex Therapeutics has a consensus price target of $16.50, indicating a potential upside of 3,027.37%. Given Enlivex Therapeutics’ higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Surrozen.

Valuation and Earnings

This table compares Surrozen and Enlivex Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48 million	83.14	-$242.03 million	($37.59)	-0.66
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($0.55)	-0.96

Enlivex Therapeutics has lower revenue, but higher earnings than Surrozen. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surrozen and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Enlivex Therapeutics	N/A	248.08%	206.39%

Insider & Institutional Ownership

66.6% of Surrozen shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.